Gabapentin (All indications) updated on 04-22-2025

Language disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19340
R82014
Moore (Controls exposed to LTG) (Indication NOS), 2025 Speech, language and communication disorders - Assessment offered to all children - At the 27–30 month during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.12 [0.90;1.39] C
excluded (control group)
227/1,128   172/934 399 1,128
ref
S19334
R82032
Moore (Controls unexposed, general pop) (Indication NOS), 2025 Speech, language and communication disorders - Assessment offered to all children - At the 27–30 months during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: No Matched 1.89 [1.62;2.21] C 227/1,128   1,324/11,276 1,551 1,128
ref
S10095
R36750
Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Visits to a speech therapist (mean age of 3.7 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.70 [0.40;1.20]
excluded (control group)
11/378   157/2,916 168 378
ref
S8517
R28097
Coste (Controls unexposed, NOS) (Mixed indications), 2020 Health care utilization: Speech therapy (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.60 [0.40;1.20] 11/378   72,012/1,710,441 72,023 378
ref
S8543
R28381
Bromley, 2016 Verbal abilities <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No 0.98 [0.10;9.53] C 1/14   4/55 5 14
ref
Total 3 studies 1.09 [0.40;2.93] 73,579 1,520
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Controls unexposed, general pop) (Indication NOS), 2025Moore, 2025 1 1.89[1.62; 2.21]1,5511,12846%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 2 0.60[0.40; 1.20]72,02337841%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Bromley, 2016Bromley, 2016 0.98[0.10; 9.53]51414%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 87% 1.09[0.40; 2.93]73,5791,5200.25.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop) (Indication NOS; 2: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.09[0.40; 2.93]73,5791,52087%NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Bromley, 2016 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.10[0.36; 3.39]73,5741,50694%NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2 unexposed, sickunexposed, sick 0.98[0.10; 9.53]514 -NABromley, 2016 1 Tags Adjustment   - No  - No 1.89[1.62; 2.21]1,5561,1420%NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 Bromley, 2016 2   - Yes  - Yes 0.60[0.35; 1.04]72,023378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 MatchedMatched 1.89[1.62; 2.21]1,5511,128 -NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 1 All studiesAll studies 1.09[0.40; 2.93]73,5791,52087%NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Bromley, 2016 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10095, 19340

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.10[0.36; 3.39]73,5741,50694%NAMoore (Controls unexposed, general pop) (Indication NOS), 2025 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2 unexposed, sick controlsunexposed, sick controls 0.98[0.10; 9.53]514 -NABromley, 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.95[0.61; 1.47]5671,50658%NAMoore (Controls exposed to LTG) (Indication NOS), 2025 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 20.510.01.0